PMID- 21143701
OWN - NLM
STAT- MEDLINE
DCOM- 20110311
LR  - 20201215
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Linking)
VI  - 102
IP  - 2
DP  - 2011 Feb
TI  - Phase I clinical trial of survivin-derived peptide vaccine therapy for patients 
      with advanced or recurrent oral cancer.
PG  - 324-9
LID - 10.1111/j.1349-7006.2010.01789.x [doi]
AB  - Survivin, a member of the inhibitor of apoptosis protein (IAP) family, is 
      abundantly expressed in most malignancies, but is hardly detectable in normal 
      adult tissues. Previously we have identified a human leukocyte antigen 
      (HLA)-A24-restricted antigenic peptide, survivin-2B80-88 (AYACNTSTL), recognized 
      by CD8(+) cytotoxic T lymphocytes (CTL). Survivin-2B80-88-specific CTL were 
      induced efficiently from peripheral blood mononuclear cells (PBMC) of oral cancer 
      patients after stimulation with the peptide in vitro. We conducted a phase I 
      clinical study to evaluate the safety and the efficacy of survivin-2B80-88 
      peptide vaccination in HLA-A24-positive patients with advanced or recurrent oral 
      cancer. The vaccines were given subcutaneously or intratumorally six times at 
      14-day intervals. Eleven patients were enrolled and 10 patients completed the 
      vaccination protocol. No adverse events were observed in any patients. In two 
      patients, the levels of serum squamous cell carcinoma (SCC) antigen decreased 
      transiently during the period of vaccination. Tumor regression that was 
      compatible with a partial response (PR) was noted in one patient. The remaining 
      nine patients experienced progressive disease (PD). Immunologically, an increase 
      of the peptide-specific CTL frequency was detected in six of the eight patients 
      evaluated by HLA-A24/peptide tetramer analysis. The present clinical trial 
      revealed that survivin-2B peptide vaccination was safe and had therapeutic 
      potential for oral cancer patients. However, subsequent clinical trials in 
      combination with various adjuvant drugs will be required to improve the 
      immunological and therapeutic efficacy. This trial was registered with University 
      Hospital Medical Information Network (UMIN) number UMIN000000976.
CI  - (c) 2010 Japanese Cancer Association.
FAU - Miyazaki, Akihiro
AU  - Miyazaki A
AD  - Department of Oral Surgery Pathology, Sapporo Medical University School of 
      Medicine, Sapporo, Japan. amiyazak@sapmed.ac.jp
FAU - Kobayashi, Junichi
AU  - Kobayashi J
FAU - Torigoe, Toshihiko
AU  - Torigoe T
FAU - Hirohashi, Yoshihiko
AU  - Hirohashi Y
FAU - Yamamoto, Takashi
AU  - Yamamoto T
FAU - Yamaguchi, Akira
AU  - Yamaguchi A
FAU - Asanuma, Hiroko
AU  - Asanuma H
FAU - Takahashi, Akari
AU  - Takahashi A
FAU - Michifuri, Yoshitaka
AU  - Michifuri Y
FAU - Nakamori, Kenji
AU  - Nakamori K
FAU - Nagai, Itaru
AU  - Nagai I
FAU - Sato, Noriyuki
AU  - Sato N
FAU - Hiratsuka, Hiroyoshi
AU  - Hiratsuka H
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
DEP - 20101210
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (Survivin)
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Neoplasm/immunology/*therapeutic use
MH  - Cancer Vaccines/*therapeutic use
MH  - Epitopes, T-Lymphocyte/immunology
MH  - Female
MH  - Humans
MH  - Immunotherapy, Active/*methods
MH  - Inhibitor of Apoptosis Proteins
MH  - Male
MH  - Microtubule-Associated Proteins/immunology/*therapeutic use
MH  - Middle Aged
MH  - Mouth Neoplasms/immunology/*therapy
MH  - Survivin
MH  - Vaccines, Subunit/therapeutic use
EDAT- 2010/12/15 06:00
MHDA- 2011/03/12 06:00
CRDT- 2010/12/15 06:00
PHST- 2010/12/15 06:00 [entrez]
PHST- 2010/12/15 06:00 [pubmed]
PHST- 2011/03/12 06:00 [medline]
AID - 10.1111/j.1349-7006.2010.01789.x [doi]
PST - ppublish
SO  - Cancer Sci. 2011 Feb;102(2):324-9. doi: 10.1111/j.1349-7006.2010.01789.x. Epub 
      2010 Dec 10.